Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human adenovirus type 5 plus neoadjuvant chemotherapy for resectable stage III lung cancer
ChiCTR2200055779Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2022
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Oncorine in bronchial carcinoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: major pathological response. Started Jan 2022; status: recruiting.
02
Drugs
Oncorine
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200055779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055779.